Amryt Pharma PLC

$7.84 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest


About Amryt Pharma PLC

Amryt Pharma plc (Amryt) is a United Kingdom-based commercial-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing treatments to help patients with rare and orphan diseases. Amryt’s commercial business comprises two orphan disease products: metreleptin (Myalept/ Myalepta) and lomitapide (Juxtapid/ Lojuxta). Myalept is approved in the United States as an adjunct to diet as replacement therapy to treat leptin deficiency in patients with congenital or acquired generalised lipodystrophy (GL). Juxtapid is approved as an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the rare cholesterol disorder, homozygous familial hypercholesterolaemia (HoFH). The Company's development candidate, Oleogel-S10 (Filsuvez) is a treatment for the cutaneous manifestations of junctional and dystrophic (JEB and DEB) epidermolysis bullosa. Amryt’s pre-clinical gene therapy platform, AP103, offers treatment for patients with DEB.

Stock Analysis

last close -
1-mo return -
3-mo return -
avg daily vol. -
52-week high -
52-week low -
market cap. -
forward pe -
annual div. -
roe -
ltg forecast -
dividend yield -
annual rev. -
inst own. -

Subscribe now for daily local and international financial news